These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1235 related articles for article (PubMed ID: 31208353)

  • 1. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the CPS+EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in China.
    Xu L; Duan X; Zhou B; Liu Y; Ye J; Liu Z; Ma C; Zhang H; Zhang S; Zhang L; Zhao J; Cheng Y
    Breast; 2018 Aug; 40():29-37. PubMed ID: 29677568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
    Kantor O; Laws A; Pastorello RG; King C; Wong S; Dey T; Schnitt S; King TA; Mittendorf EA
    Ann Surg Oncol; 2021 Nov; 28(12):7347-7355. PubMed ID: 33956276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
    Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
    Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Bergquist JR; Murphy BL; Storlie CB; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 Nov; 24(12):3510-3517. PubMed ID: 28828583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
    Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors.
    Yi M; Lin H; Bedrosian I; Shen Y; Hunt KK; Chavez-MacGregor M; King TA; Mittendorf EA
    Ann Surg Oncol; 2020 Feb; 27(2):359-366. PubMed ID: 31667721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.
    Soares ICS; Bello MA; Bergmann A; Thuler LCS
    Breast Cancer Res Treat; 2021 Jun; 187(2):547-555. PubMed ID: 33417086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A study on the correlation between Neo-Bioscoresystem and disease-free survival of breast cancer patients with neoadjuvant chemotherapy].
    Wang GC; Xu FR; Li JB; Liu W; Bian L; Zhang SH; Wang T; Song ST; Jiang ZF
    Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(30):2349-2352. PubMed ID: 28822452
    [No Abstract]   [Full Text] [Related]  

  • 19. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
    Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
    Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy.
    Hasegawa Y; Matsubara N; Kogawa T; Naito Y; Harano K; Hosono A; Onishi T; Hojo T; Shimokawa M; Mukohara T
    In Vivo; 2021; 35(2):1041-1049. PubMed ID: 33622900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.